Display options
Cite
Silas JH, Phillips FC, Freestone S, et al. A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. Eur J Clin Pharmacol. 1981;19(2):113-8doi: 10.1007/BF00568397.
Silas, J. H., Phillips, F. C., Freestone, S., Tucker, G. T., & Ramsay, L. E. (1981). A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. European journal of clinical pharmacology, 19(2), 113-8. https://doi.org/10.1007/BF00568397
Silas, J H, et al. "A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients." European journal of clinical pharmacology vol. 19,2 (1981): 113-8. doi: https://doi.org/10.1007/BF00568397
Silas JH, Phillips FC, Freestone S, Tucker GT, Ramsay LE. A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. Eur J Clin Pharmacol. 1981 Jan;19(2):113-8. doi: 10.1007/BF00568397. PMID: 7202470.
Copy Download .nbib Format: NLM
Share it on
Full text links
Springer

Eur J Clin Pharmacol. 1981 Jan;19(2):113-8. doi: 10.1007/BF00568397.

A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients.

European journal of clinical pharmacology

J H Silas, F C Phillips, S Freestone, G T Tucker, L E Ramsay

PMID: 7202470 DOI: 10.1007/BF00568397

Abstract

The pharmacokinetics, hypotensive effect and tolerability of a new vasodilator, tolmesoxide (T), have been studied in 6 uncontrolled hypertensive patients receiving atenolol and diuretic. After a 50 mg oral dose mean (+/- SD) peak plasma concentration of T was 1.13 +/- 0.29 micrograms/ml-1 and occurred 0.79 +/- 0.40 h after the dose; mean peak plasma concentration of its sulphone metabolite (M) was 0.37 +/- 0.09 micrograms/ml-1 at 1.92 +/- 1.32 h after the dose. Following peak plasma concentrations there was a monoexponential decline in T and M concentrations with half-lives of 2.78 +/- 0.77 h and 10.78 +/- 7.85 h respectively. There was a linear increase in plasma concentration of T and M during incremental dosing with 50--200 mg t.i.d. During in-patient administration of 600--900 mg T daily (n = 6) there was no significant change in blood pressure, pulse rate or body weight. Out-patient administration of 900 mg T daily (n = 4) was associated with a significant fall in mean systolic but not diastolic by (lying -15/+1 mm Hg. standing -25/-8 mm Hg). A further fall was observed in 2 subjects receiving 1200 mg and 1500 mg daily. Supine pulse rate increased (mean +/- SD) significantly from 55 +/- 5/min to 66 +/- 8/min following 900--1500 mg T in 4 out-patients. Severe nausea and other gastro-intestinal side-effects in all subjects receiving 600--900 mg daily eventually necessitated drug withdrawal. In its present form T is not recommended for the treatment of hypertension.

References

  1. Br Med J. 1977 Aug 27;2(6086):547-50 - PubMed
  2. Clin Sci Mol Med Suppl. 1976 Dec;3:579s-581s - PubMed
  3. Acta Cardiol. 1977;32(4):283-93 - PubMed
  4. Br Heart J. 1980 Feb;43(2):202-5 - PubMed
  5. Am J Med. 1973 Jan;54(1):58-72 - PubMed
  6. N Engl J Med. 1976 Apr 22;294(17):930-6 - PubMed
  7. Br J Pharmacol. 1978 May;63(1):111-8 - PubMed
  8. Circulation. 1972 Mar;45(3):571-82 - PubMed
  9. Am Heart J. 1978 Jan;95(1):1-3 - PubMed
  10. N Engl J Med. 1975 Aug 7;293(6):280-5 - PubMed
  11. JAMA. 1977 May 23;237(21):2303-10 - PubMed
  12. Br J Clin Pharmacol. 1978 Jan;5(1):35-44 - PubMed
  13. Br J Clin Pharmacol. 1979 Oct;8(4):402P - PubMed
  14. Eur J Clin Pharmacol. 1981 Jan;19(2):119-25 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources